Company: Calistoga Pharmaceuticals
Based: Seattle, WA
Investors: Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners
Scoop: Since its $40.22 million Series C round, Calistoga has continued to turn heads, most recently from its $600 million buyout by Gilead Sciences. Their last funding round brought the company's total VC take to $100 million over four years, mostly for its cancer drug CAL-101 and a rheumatoid arthritis treatment. The company received $375 million upfront from Gilead, and stands to make another $225 million through milestone payments.